Selectively targeting key inflammatory pathways in cystic fibrosis

Area of Science:

• Pulmonology
• Immunology
• Genetics

Background:

• Cystic fibrosis (CF) is a genetic disorder caused by defective Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein.
• Respiratory complications, including chronic inflammation and recurrent infections, are the primary cause of mortality in CF patients.
• While CFTR modulators are a breakthrough, their effect on inflammation remains unclear.

Purpose of the Study:

• To review anti-inflammatory drugs for CF.
• To explore targeting inflammation as a therapeutic strategy for CF lung disease.
• To investigate novel therapeutics based on defective immune pathways in CF.

Main Methods:

• Overview of approved and investigational anti-inflammatory drugs in CF.
• Analysis of recent studies on immune pathways in CF.
• Exploration of naturally occurring molecules and synthetic mimics for targeted therapy.

Main Results:

• Inflammation is a critical, yet often overlooked, therapeutic target in CF.
• Balancing anti-inflammatory effects with infection risk is crucial.
• Targeting defective endogenous immunoregulatory pathways offers a promising therapeutic avenue.

Conclusions:

• Selective targeting of key inflammatory pathways is essential for preserving lung function and immunocompetence in CF patients.
• Innovative therapeutics derived from understanding CF immune defects are under development.
• Restoring homeostatic inflammation regulation is vital for managing CF lung disease.